Challenges And Opportunities At The New Cytiva
CEO Emmanuel Ligner Outlines Future At Biopharma’s Biggest Manufacturing Business
In 2019, more than 75% of the biological therapies approved by the FDA used technologies developed by GE Healthcare Life Sciences for manufacturing. Following the completion of a $21.9bn acquisition by Danaher, the company has rebranded to Cytiva. In Vivo speaks with CEO Emmanuel Ligner to learn more about his vision for the new company and the impact of COVID-19.
You may also be interested in...
Wound care company MiMedx has raised $150m in private equity and debt financing from EW Healthcare Partners and Hayfin Capital Management. The funds will be used to scale commercialization of the company’s amniotic tissue products.
The UK government has ordered 65 million needles and syringes from Becton Dickinson to support future vaccination efforts for COVID-19. The order is expected to be delivered by September 2020.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the pandemic. Medtech start-ups raised more than $1.5bn with Medtech Insight tracking over 40 financial deals of $1m-and-over.